Latest Information Update: 08 Aug 1994
At a glance
- Originator Eli Lilly
- Class Anti-ischaemics; Plasminogen activator enzymes; Thrombolytics
- Mechanism of Action Plasminogen activators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Coronary thrombosis; Myocardial infarction